The Vail Valley's Only Young Professional Organization
The Vail Valley Young Professionals Association hosts and sponsors an array of events including – networking events, happy hours, meet and greet sessions with major Vail Valley and Colorado decision-makers and community focused events. The VVYPA is an ideal place for young professionals to develop themselves professionally, socially, and civically.
CANCER. It’s the disease Americans fear most, the disease we most want to cure. It can be devastating for a patient, a family, or a community, instantly reminding us how precious life is and inspiring us to rally around a common goal.
Research advances over the past three decades have yielded great successes in improving patient survival and in achieving cures for common cancers such as breast cancer, ovarian cancer, lung cancer, esophageal cancer and prostate cancer.
With the rare opportunity to host five specialists from the University of Michigan Comprehensive Cancer Center (UMCCC), the Vail Symposium will present a two-part panel program where everyone–medical doctors and patients to those simply interested in learning about measures of treatment and prevention of common cancers–can grasp exciting new breakthroughs in cancer research.
Meet the Panel:
Dr. Eric Fearon was named Director at the UMCCC in September of 2016. He is a Professor of Oncology and also a Professor in the Departments of Internal Medicine, Human Genetics, and Pathology at the University of Michigan Medical School. Dr. Fearon has authored more than 135 peer-reviewed research manuscripts and more than 60 review/editorial articles and book chapters. He has pursued research in the cancer genetics field, particularly investigations of selected gene defects that underlie colon and rectal tumor development and progression to advanced stages. He is currently an editorial board member or editor at 10 journals, including The Journal of Biological Chemistry, Current Biology, Journal of Clinical Investigation, and Gastroenterology.
Arul M. Chinnaiyan, is a Howard Hughes Medical Institute Investigator, American Cancer Society Research Professor, and S.P. Hicks Endowed Professor of Pathology and Urology at the University of Michigan. He has co-authored over 400 manuscripts and has been designated an A. Alfred Taubman Medical Research Institute Scholar. Dr. Chinnaiyan’s research has focused on functional genomic and bioinformatics approaches to study cancer for the purposes of understanding cancer biology as well as to discover clinical biomarkers. Specialty: Prostate Cancer
Dr. Kathleen R. Cho is the head of the gynecologic pathology section of Surgical Pathology at the University of Michigan Health System. Dr. Cho has established a research laboratory that uses a range of systems and approaches to study the molecular pathogenesis of ovarian cancers. These include technologies to generate comprehensive molecular profiles of primary human carcinomas and their precursors, in vitro systems to study altered signaling pathways and effects of specific molecular alterations in cancer cells, and genetically engineered mouse models of cancer. Specialty: Ovarian Cancer
Dr. Elizabeth Lawlor, associate director for education and training, is the Russell G. Adderley Professor of Pediatric Oncology Research and an associate professor in the departments of Pediatrics and Pathology at the University of Michigan Medical School. She received her medical degree from McMaster University in Ontario, Canada, and her doctorate in cancer biology from the University of British Columbia in Vancouver, Canada. She completed clinical and research fellowships in pediatric hematology/oncology and bone marrow transplantation at British Columbia Children’s Hospital, and post-doctoral training at the University of California San Francisco Cancer Research Institute. She joined the University of Michigan faculty in 2010 from Children’s Hospital Los Angeles and the University of Southern California. Lawlor’s research focuses on understanding how hijacking of normal stem cell and developmental processes contributes to the initiation and progression of Ewing sarcoma.
Dr. Sofia Diana Merajver, an expert in breast cancer genetics, is the medical director of the Breast and Ovarian Cancer Risk Evaluation Program at the U-M Cancer Center. Dr. Sofia Merajver received a doctoral degree in physics from the University of Maryland and a medical degree from the University of Michigan. She completed a residency in internal medicine and a fellowship in oncology at the University of Michigan before joining the faculty in 1994. Her research interests include the molecular genetics of breast cancer, gene function and cancer risk assessment.
Specialty: Breast Cancer
Free for current VVYPA members. Membership info at www.vvypa.com.
Event info at VailSymposium.org